Table 1.
Ongoing tenecteplase randomized controlled trials.
| Number of anticipated enrolled patients | Posterior circulation stroke patients | Primary outcome | Primary hypothesis | Clinicaltrials.gov registration (or Australian New Zealand registration) number | |
|---|---|---|---|---|---|
| TASTE | n = 1,024 | YES | mRS 0–1 (no disability) at 90 days | Tenecteplase 0.25 mg/kg is superior to alteplase 0.9 mg/kg within 4.5 h after symptom onset in patients with acute ischaemic stroke eligible for intravenous thrombolysis and with target mismatch on computed tomography perfusion imaging | ACTRN12613000243718 |
| ATTEST-2 | n = 1,870 | YES | Ordinal mRS analysis at 90 days | Tenecteplase 0.25 mg/kg is superior to alteplase 0.9 mg/kg within 4.5 h after symptom onset in patients with acute ischaemic stroke eligible for intravenous thrombolysis | NCT02814409 |
| AcT | n = 1,600 | YES | mRS 0–1 (no disability) at 90 days | Tenecteplase 0.25 mg/kg is non-inferior to alteplase 0.9 mg/kg within 4.5 h after symptom onset in patients with acute ischaemic stroke eligible for intravenous thrombolysis | NCT03889249 |
| NOR-TEST2 | n = 1,342 | YES | mRS 0–1 (no disability) at 90 days | Tenecteplase 0.4 mg/kg is superior to alteplase 0.9 mg/kg in patients with acute ischaemic stroke treated within 4.5 h after symptom onset (or after awakening with stroke symptoms) | NCT03854500 |
| TEMPO-2 | n = 1,274 | YES | Return to baseline mRS at 90 days | Tenecteplase 0.25 mg/kg is superior to standard of care in minor ischaemic stroke patients with proven acute symptomatic intracranial occlusion within 12 h after symptom onset | NCT02398656 |
| ETERNAL-LVO | n = 740 | NO | mRS 0–1 (no disability) or return to baseline mRS at 90 days | Tenecteplase 0.25 mg/kg is superior to current best practice in acute ischaemic stroke patients with a large-vessel occlusion and penumbral tissue on multimodal CT or MRI within 24 h after symptom onset | NCT04454788 |
| TIMELESS | n = 456 | NO | Ordinal mRS analysis at 90 days | Tenecteplase 0.25 mg/kg is superior to placebo in patients with acute ischaemic stroke with a large-vessel occlusion and penumbral tissue between 4.5 and 24 h after symptom onset | NCT03785678 |
| TWIST | n = 600 | YES | Ordinal mRS analysis at 90 days | Tenecteplase 0.25 mg/kg is superior to best standard treatment in acute ischaemic stroke patients within 4.5 h of awakening with stroke symptoms | NCT03181360 |
| TASTE-A | n = 80 | YES | Volume of lesion on CT Perfusion performed on arrival at the receiving hospital | Tenecteplase 0.25mg/kg is superior to alteplase 0.9mg/kg in acute ischaemic stroke patients eligible for intravenous thrombolysis and attended by a mobile stroke unit | NCT04071613 |
mRS, modified Rankin Scale score; TASTE, Tenecteplase vs. Alteplase for Stroke Thrombolysis Evaluation Trial; ATTEST-2, Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis trial; AcT, Alteplase Compared to Tenecteplase in Patients With Acute Ischemic Stroke trial; NOR-TEST2, The Norwegian Tenecteplase Stroke Trial 2; TEMPO-2, TNK-tPA vs. Standard of Care for Minor Ischemic Stroke With Proven Occlusion Trial; ETERNAL-LVO, Extending the Time Window for Tenecteplase by Effective Reperfusion in Patients With Large Vessel Occlusion Trial; TIMELESS, Tenecteplase in Stroke Patients Between 4.5 and 24 h Trial; TWIST, Tenecteplase in Wake-up Ischaemic Stroke Trial; TASTE-A, Tenecteplase vs. Alteplase for Stroke Thrombolysis Evaluation Trial in the Ambulance.